Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2019
Conference Publication
Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Blacklock, Hilary, Moore, Elizabeth, Wellard, Cameron, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Mollee, Peter, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.354
2019
Conference Publication
Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant
Gries, Katharine, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Orlowski, Robert Z., Bahlis, Nizar J., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Hulin, Cyrille, Weisel, Katja, He, Jianming, Ho, Kai Fai, Wang, Jim, Van Rampelbergh, Rian, Uhlar, Clarissa, Kobos, Rachel and Perrot, Aurore (2019). Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.375
2019
Journal Article
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458
2019
Journal Article
Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration
Tobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365
2019
Journal Article
Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registry
Ho, P. Joy, Moore, Elizabeth M., McQuilten, Zoe K., Wellard, Cameron, Bergin, Krystal, Augustson, Bradley, Blacklock, Hilary, Harrison, Simon J., Horvath, Noemi, King, Tracy, Mollee, Peter, Quach, Hang, Reid, Christopher, Rosengarten, Brian, Walker, Patricia, Wood, Erica M. and Spencer, Andrew (2019). Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registry. Clinical Lymphoma, Myeloma and Leukemia, 19 (8), e415-e424. doi: 10.1016/j.clml.2019.05.010
2019
Conference Publication
Lysozyme amyloidosis – Two novel cases with newly described genetic mutations
McMichael, L., Chang, S., Gibbs, S., Mollee, P., Gillmore, J., Horvath, N., Crail, S. and Jobert, A. (2019). Lysozyme amyloidosis – Two novel cases with newly described genetic mutations. ISN World Congress of Nephrology (WCN) 2024, Buenos Aires, Argentina, 13-16 April 2024. New York, NY United States: Elsevier. doi: 10.1016/j.ekir.2019.05.590
2019
Journal Article
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy
Tate, Courtney, Burgess, Melinda, McMillan, Nigel A., Saunders, Nicholas A., Cheung, Catherine, Gill, Devinder and Mollee, Peter (2019). High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy. Leukemia and Lymphoma, 60 (10), 1-5. doi: 10.1080/10428194.2019.1581936
2019
Conference Publication
Validation of the Boston University staging system in AL amyloidosis
Tomlinson, R., Matigain, N. and Mollee, P. (2019). Validation of the Boston University staging system in AL amyloidosis. 29th European Hematology Association Congress EHA24, Madrid, Spain, 13-16 June 2024. Philadelphia, PA United States: Wiley. doi: 10.1097/01.hs9.0000567024.85321.eb
2019
Journal Article
The epidemiology of amyloidosis in Queensland, Australia
Wisniowski, Brendan, McLeod, Donald, Adams, Rebecca, Harvey, Yasmin, Brown, Ian, McGuire, Lloyd, Armes, Jane and Mollee, Peter (2019). The epidemiology of amyloidosis in Queensland, Australia. British Journal of Haematology, 186 (6) bjh.16000, 829-836. doi: 10.1111/bjh.16000
2019
Journal Article
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O'Dwyer, Michael, Perrot, Aurore, Venner, Christopher P., Weisel, Katja, Mace, Joseph R., Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Qi, Ming ... Mollee, Peter (2019). Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. The New England Journal of Medicine, 380 (22), 2104-2115. doi: 10.1056/NEJMoa1817249
2019
Journal Article
Validation of the Boston University staging system in AL amyloidosis
Tomlinson, Ross, Matigian, Nicholas and Mollee, Peter (2019). Validation of the Boston University staging system in AL amyloidosis. Amyloid: Journal of Protein Folding Disorders, 26 (3), 1-3. doi: 10.1080/13506129.2019.1608941
2019
Conference Publication
The epidemiology of amyloidosis in Australia
Wisniowski, Brendan, McLeod, Donald, Adams, Rebecca, Harvey, Yasmin, Armes, Jane, Papadimos, David, Brown, Ian, McGuire, Lloyd and Mollee, Peter (2019). The epidemiology of amyloidosis in Australia. XVI International Symposium on Amyloidosis, Kumamoto, Japan, 26-29 March 2018. Abingdon, Oxfordshire United Kingdom: Taylor & Francis. doi: 10.1080/13506129.2019.1582481
2019
Journal Article
Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement
Chin, C. K., Tsang, E., Mediwake, H., Khair, W., Biccler, J., Hapgood, G., Mollee, P., Nizich, Z., Joske, D., Radeski, D., Cull, G., Villa, D., El-Galaly, T. C. and Cheah, C. Y. (2019). Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement. British Journal of Haematology, 184 (5), 826-828. doi: 10.1111/bjh.15173
2019
Journal Article
Paraprotein sample exchange in Australia and New Zealand - 2018
Wijeratne, Nilika, Tate, Jillian R., Toit, Stephen Du, Smith, Joel D., Soepnel, Andrew, Choy, Kay Weng, Martin, Helen, Henry, Robyn, Glegg, Kaye, Byrnes, Elizabeth, Wienholt, Louise and Mollee, Peter (2019). Paraprotein sample exchange in Australia and New Zealand - 2018. Clinical Biochemist Reviews, 40 (1), 43-54.
2019
Journal Article
Amyloidosis in Australia
Mollee, Peter, Gibbs, Simon and Stewart, Graeme (2019). Amyloidosis in Australia. Expert Opinion on Orphan Drugs, 7 (2), 37-39. doi: 10.1080/21678707.2019.1563539
2019
Journal Article
Report of the survey conducted by RCPAQAP on current practice for paraprotein and serum free light chain measurement and reporting: A need for harmonisation
Wijeratne, Nilika, Tate, Jillian R., Wienholt, Louise and Mollee, Peter (2019). Report of the survey conducted by RCPAQAP on current practice for paraprotein and serum free light chain measurement and reporting: A need for harmonisation. Clinical Biochemist Reviews, 40 (1), 31-42.
2019
Journal Article
Proposed addendum to 2012 recommendations for standardised reporting of protein electrophoresis in Australia and New Zealand
Tate, Jillian R., Smith, Joel D., Wijeratne, Nilika and Mollee, Peter (2019). Proposed addendum to 2012 recommendations for standardised reporting of protein electrophoresis in Australia and New Zealand. Clinical Biochemist Reviews, 40 (1), 23-30.
2019
Journal Article
Response to article by Caponi et al. about serum free light chains
Tate, Jillian R., Hawley, Carmel and Mollee, Peter (2019). Response to article by Caponi et al. about serum free light chains. Clinical Chemistry and Laboratory Medicine, 57 (2), e1-e2. doi: 10.1515/cclm-2018-0994
2019
Conference Publication
Beta-migrating paraproteins: a need for harmonisation of reporting
Wijeratne, Nilika, Tate, Jillian R., Du Toit, Stephen, Smith, Joel D., Soepnel, Andrew, Choy, Kay Weng, Martin, Helen, Henry, Robyn, Glegg, Kaye, Byrnes, Elizabeth, Wienholt, Louise and Mollee, Peter (2019). Beta-migrating paraproteins: a need for harmonisation of reporting. Pathology Update 2019, Melbourne, VIC Australia, 22-24 February 2019. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2018.12.323
2019
Journal Article
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Leung, Nelson, Bridoux, Frank, Batuman, Vecihi, Chaidos, Aristeidis, Cockwell, Paul, D’Agati, Vivette D., Dispenzieri, Angela, Fervenza, Fernando C., Fermand, Jean-Paul, Gibbs, Simon, Gillmore, Julian D., Herrera, Guillermo A., Jaccard, Arnaud, Jevremovic, Dragan, Kastritis, Efstathios, Kukreti, Vishal, Kyle, Robert A., Lachmann, Helen J., Larsen, Christopher P., Ludwig, Heinz, Markowitz, Glen S., Merlini, Giampaolo, Mollee, Peter, Picken, Maria M., Rajkumar, Vincent S., Royal, Virginie, Sanders, Paul W., Sethi, Sanjeev, Venner, Christopher P. ... Nasr, Samih H. (2019). The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 15 (1), 45-59. doi: 10.1038/s41581-018-0077-4
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: